How Much Can You Make Selling a Patent? Gross vs Net

How much can you make selling a patent? Less than the price, and by how much depends on three things most answers skip: who takes a cut, how the money is paid, and how the tax authority classifies it. Two sellers can agree the same headline number and walk away with very different amounts.

This piece is about the gap between the two numbers. If you want the price side first, meaning ranges, medians and what pushes an asset into the top quartile, start with what patents actually sell for. Here we take the price as given and work toward what reaches your account.

Price is what the buyer pays. What you make is a different number

One anchor to keep in mind: across US patent transactions, the median sits at roughly 77,000 USD. Most individual sellers will land nearer that figure than the headline deals that get written up.

From whatever price you agree, three things come off:

1. Transaction costs. Broker or marketplace fees, attorney time on the assignment, and the maintenance fees you kept paying while the asset was on the market.
2. Structure risk. Money promised over time is not money received. Anything contingent on the buyer's future sales carries the buyer's execution risk.
3. Tax. The character of the income, capital gain or ordinary income, can move the net more than a few points of commission ever will.

Three ways the money can arrive

Lump sum

The cleanest version: you assign the patent, the buyer wires the money, you are done. Ranges quoted online are wide. One guide puts most patent sales between 10,000 and 500,000 USD, with high value assets in active markets selling for millions. Channel matters too. An inventor approaching corporations cold, where it is obvious they want to sell, may attract 5,000 to 35,000 USD. Motivated sellers are priced like motivated sellers.

A lump sum is the lowest risk way to get paid and usually the lowest gross number. That trade is the whole point of it.

Installments or payments tied to the buyer's use

A sale does not have to be paid on day one. Buyers sometimes offer a smaller upfront amount plus payments that track their use of the patent or their sales of the product. This closes the valuation gap when buyer and seller disagree on what the asset will earn: you get more if it works, they pay less if it does not.

The catch is that you are now exposed to the buyer. If they shelve the product, get acquired, or simply stop selling, the tail payments shrink. Treat contingent money as an option, not as income.

Licensing instead of selling

Keep the patent and rent it out. Licensees typically pay an upfront fee plus a running royalty, which the same guide puts at around 2 to 5 percent of sales for consumer products and higher for specialised technology (our longer breakdown of average patent licensing royalty rates goes sector by sector).

Licensing advocates argue the gross is far larger. One advisory firm's worked example compares a 2 million dollar sale against a 10 year licence at 5 percent of 8 million in annual revenue plus a 200,000 upfront fee, totalling 4.2 million. That arithmetic assumes the licensee's revenue projection holds for a decade, that nobody designs around the claims, and that you can afford to enforce the licence if they stop paying. It also compares pre tax numbers, which is where the comparison starts to break.

Tax decides more of the answer than most sellers expect

We are not tax advisors and nothing here is tax advice. What follows is the US statutory position in general terms, so you know which questions to bring to someone who is. Other countries treat this differently; German sellers in particular should get local advice.

What Section 1235 gives an individual inventor

The US tax code has a rule written specifically for patent sales. Under 26 U.S. Code Section 1235, a transfer of all substantial rights to a patent by a holder is treated as the sale of a capital asset held for more than one year. That is long-term capital gain treatment, regardless of how long you actually held the patent.

The part most sellers miss: this applies regardless of whether payments are made periodically over the buyer's use of the patent, or are contingent on its productivity, use or disposition. In plain terms, a qualifying sale can be paid like a royalty and still be taxed like a sale.

A "holder" is the individual whose efforts created the invention, or an individual who paid the creator for an interest before the invention was actually reduced to practice, provided they are not the creator's employer or a related person.

Who does not qualify

The implementing regulation is explicit that a transfer by someone who is not a holder, or by a holder to a related person, is not governed by Section 1235. Corporations are not holders. If your patent sits inside your company, or you are selling to a business you control or to family, the special rule does not apply and the general rules decide. The same regulation notes that qualifying payments are purchase price for the buyer, not royalties.

The other trap is "all substantial rights". Keep back a field of use, a territory, or a right that has real value, and the deal can look more like a licence than a sale.

Why a licence is taxed differently

Royalty income from a licence is generally ordinary income. For individuals, one practitioner analysis puts the gap plainly: capital gains are taxed at a maximum 20 percent rate while ordinary income is taxed at a maximum 37 percent, and royalties get no basis offset. The same analysis notes a 3.8 percent net investment income tax may also apply to sales.

That 17 point difference is why the licensing versus selling comparison has to be run after tax, not before.

Running the arithmetic from gross to net

An illustration, not a forecast. Suppose a US individual inventor agrees a 300,000 USD sale of a granted patent and uses a full service broker. Broker commissions typically run 20 to 40 percent of the net sale price, scaling down for larger deals. At 30 percent, 90,000 goes to the broker and 210,000 remains before legal costs on the assignment.

If the sale qualifies under Section 1235 and the seller is in the top bracket, the maximum federal rate on the gain is 20 percent, plus up to 3.8 percent if the net investment income tax applies, less whatever basis the seller has. On those assumptions, the seller keeps somewhere in the region of 160,000 of the 300,000 headline. Change the assumptions, lower bracket, cheaper channel, state tax, and the number moves. The structure of the calculation does not.

Now run the same seller through a licence producing 300,000 of royalties. No commission, perhaps, but ordinary income rates up to 37 percent, collection risk every year, and the patent still on your books with its maintenance fees and enforcement burden. Sometimes that still wins. It should win on after tax, risk adjusted numbers, not on the gross.

Fees are the one line you can negotiate hardest before you sign. Our breakdown of how patent brokers charge walks through retainers, success fees and the clauses that cost more than the headline rate.

Where EX IX fits, and what we will not tell you

We run a patent brokerage, so we have a stake in this answer. Our model is success based: the seller pays commission on completion, the minimum fee is EUR 5,000 per completed transaction, and no sale means no fee. That aligns us with the sale closing, not with the process running long.

Two limits, stated plainly. EX IX is not a firm of patent attorneys, and we are not tax advisors. We can tell you whether there is a buyer and roughly what the buyer's alternative costs them. Whether your sale qualifies under Section 1235, and what your personal rate will be, is a conversation for a tax professional before you sign the assignment, because the structure is much harder to fix afterwards.

And no one, including us, can promise a sale will happen or at what price. Many patents never find a buyer. If you want the mechanics of the process from first contact to assignment, see how selling a patent works.

FAQ

Is money from selling a patent taxed as capital gains?

Often, for a US individual inventor. If you are a holder under Section 1235 and transfer all substantial rights to someone who is not a related person, the gain is treated as long-term capital gain whatever your holding period. Corporate sellers and transfers to related parties fall under the general rules instead.

Can I sell a patent and still get paid like a royalty?

Yes. Section 1235 expressly covers payments made periodically over the buyer's use or contingent on the patent's productivity. The deal still has to transfer all substantial rights, and you carry the buyer's performance risk on every future payment.

Is licensing always worth more than selling?

Not after tax and risk. A licence can produce a larger gross over the patent's life, but royalties are generally ordinary income, you remain responsible for maintenance and enforcement, and the payments depend on the licensee's continued sales.

Does selling before grant change how much I make?

It lowers the price, often sharply, because the buyer takes on examination risk. A pending application also complicates the "all substantial rights" analysis, which is one more reason to take tax advice before signing.